Clinical Trials Logo

Filter by:
NCT ID: NCT05757089 Recruiting - Alcohol Drinking Clinical Trials

Efficacy of the Dietary Food Supplement ALCOFILTRUM in Alleviating Alcohol Hangover Symptoms

Start date: March 3, 2022
Phase: N/A
Study type: Interventional

The aim of this open-label, randomized, crossover, comparative pilot study is to assess efficacy and safety of the dietary food supplement ALCOFILTRUM in healthy volunteers who consume alcohol. Specifically the study will evaluate: - Efficacy of the intervention to alleviate hangover symptoms in participants who consumed alcohol, - Safety of intervention in participants who consuming alcohol. Participants will take four tablets of ALCOFILTRUM dietary food supplement 30 minutes before alcohol ingestion, while the control group will intake only alcohol drink.

NCT ID: NCT05751928 Recruiting - Melanoma (Skin) Clinical Trials

A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma

NEO-MIMAJOR
Start date: March 2023
Phase: Phase 3
Study type: Interventional

This study is an open-label, randomized, comparative phase III study, which will include subjects with resectable stage III skin melanoma (up to 3 resectable transient metastases are acceptable).

NCT ID: NCT05747261 Recruiting - Clinical trials for Spinal Muscular Atrophy (SMA)

Study of the Safety and Efficacy of an Adeno-Associated Viral Vector Carrying the SMN Gene After a Single Intravenous Administration of Escalating Doses in Children With Spinal Muscular Atrophy (BLUEBELL)

BLUEBELL
Start date: February 2, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this multicenter, open-label, non-comparative, cohort study is to investigate the safety, immunogenicity, and efficacy of ANB-004 in children with spinal muscular atrophy. The study will have a standard 3+3 dose-escalation design.

NCT ID: NCT05732805 Recruiting - Melanoma Clinical Trials

A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma

OCTAVA
Start date: August 2, 2022
Phase: Phase 3
Study type: Interventional

The aim of study is to investigate the efficacy, safety, immunogenicity, pharmacokinetics, and pharmacodynamics of BCD-217 followed by prolgolimab monotherapy versus prolgolimab monotherapy as first-line therapy in subjects with unresectable or metastatic melanoma.

NCT ID: NCT05689177 Enrolling by invitation - Humoral Immunity Clinical Trials

Humoral Immunity Study After a Booster Dose of Soberana Plus (FINLAY-FR-1A) Vaccine Against COVID-19

Start date: December 9, 2022
Phase: N/A
Study type: Interventional

To evaluate the dynamics of IgG levels to the SARS-CoV-2 virus after a booster dose of Soberana Plus vaccine.

NCT ID: NCT05535803 Enrolling by invitation - Tracheal Stenosis Clinical Trials

Treatment of Laryngotracheal Stenosis Using Mesenchymal Stem Cells

Start date: June 1, 2021
Phase: Phase 2
Study type: Interventional

The trial evaluates the safety and efficacy of the olfactory mucosa-derived mesenchymal stem cells based therapy for the patients with chronic laryngeal and tracheal stenosis

NCT ID: NCT05520125 Not yet recruiting - Clinical trials for Segmental Fracture - Bone Loss

Treatment of Patients With Bone Tissue Defects Using Mesenchymal Stem Cells Enriched by Extracellular Vesicles

Start date: November 1, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Treatment of patients with segmental bone tissue defects using mesenchymal stem cells enriched by extracellular vesicles

NCT ID: NCT05520112 Not yet recruiting - Clinical trials for Recurrent Pregnancy Loss

Treatment of Recurrent Pregnancy Loss Using Mesenchymal Stem Cells

Start date: November 1, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Treatment of Recurrent pregnancy loss using mesenchymal stem cells capable of differentiation in the endometrial-decidual direction.

NCT ID: NCT05335213 Recruiting - Liver Cirrhosis Clinical Trials

Urinary Tract Infections in Cirrhosis

Start date: January 5, 2022
Phase:
Study type: Observational [Patient Registry]

Evaluate the prevalence and types of urinary tract infections, the features of the gut and urinary tract microbiota in cirrhosis, to assess its importance in the development of complications and outcomes of cirrhosis.

NCT ID: NCT05334693 Recruiting - Clinical trials for Acute Myeloid Leukemia

Expanded Haploidentical Natural Killer Cells as Consolidation Strategy for Children/Young Adults With AML

Start date: November 1, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to estimate the efficacy of immunotherapy with ex vivo expanded haploidentical NK cells as consolidation therapy for children/young adults with intermediate risk AML.